Juvenescence and the Buck Institute launch Selah Therapeutics, targeting heart disease
Juvenescence & the Buck Institute announce a new joint venture with the formation of Selah Therapeutics Limited (“Selah”). Selah focuses on developing ketone-based therapies to treat heart fail...
Juvenescence Ltd. Portfolio Company Hails Successful Limb Regeneration in Adult Frogs
Morphoceuticals Inc., a portfolio company of Juvenescence Ltd., hailed the results of a long-term study published by its founders in Science Advances showing the successful regeneration of limbs in...
Juvenescence and the Buck Institute launch BHB Therapeutics
Juvenescence and the Buck Institute for Research on Aging announce a new collaboration with the formation of BHB Therapeutics a joint venture.
Juvenescence, The Buck Institute, and Insilico Medicine establish Napa Therapeutics
Juvenescence, The Buck Institute for Research on Aging, and Insilico Medicine announced today that they have formed Napa Therapeutics, to develop drugs against a novel aging-related target.